Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INB03 for Pulmonary Complications in COVID-19
NCT04370236Phase 3Terminated
- Sponsor
- INmune Bio Inc.
- Start
- Oct 2020
- Primary completion
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Placebo + Standard of Care with INB03 + Standard of Care (2 arms). Primary endpoint: Proportion of Patients With Disease Progression at 28 days. Started Oct 2020; status: terminated.
02
Drugs
pegipanermin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04370236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04370236.